HRQoL Survey Among Patients Suffering from Myopia
Research type
Research Study
Full title
Health-Related Quality of Life Survey Among Patients Suffering from Myopia or its Long-Term Consequences
IRAS ID
363529
Contact name
Julie Boelen
Contact email
Sponsor organisation
Santen SA
Clinicaltrials.gov Identifier
NCT06912802, ClinicalTrials.gov
Duration of Study in the UK
0 years, 6 months, 1 days
Research summary
This study aims to assess the impact of myopia (near-sightedness) on health-related quality of life (HRQoL) in children and adolescents, and adults. Myopia is the most common refractive error globally, and if left untreated, it can lead to severe eye diseases in adulthood (cataract, macular degeneration, open-angle glaucoma, and retinal detachment, visual impairment/legal blindness). Given the increasing prevalence of myopia, understanding its effects on quality of life is crucial for informing healthcare policies, interventions, and cost-effectiveness models. The research seeks to fill gaps in existing literature by providing data on HRQoL, healthcare resource utilization, and treatment satisfaction, which will help improve myopia management and access to treatments.
The study focuses on myopia and its complications. It does not involve testing a specific drug, device, or procedure, but rather aims to collect data that will inform cost-effectiveness models for interventions. Participants will include parents or proxies of children aged 5 years or older diagnosed with myopia (low, moderate, or high), as well as adults suffering from myopia and a long-term-related complication (cataract, macular degeneration, open-angle glaucoma, and retinal detachment, visual impairment/legal blindness).
The study will be conducted across multiple European countries, including the UK, France, Germany, Italy, Spain, Denmark, and Sweden. Participants will complete a single online survey, which will assess various aspects of myopia management, including treatment satisfaction and healthcare utilization. The survey will not involve longitudinal follow-up or data collection on treatment efficacy or adverse events.
Overall, the study aims to collect cost and quality of life data with the goal of enhancing access to myopia treatments.REC name
West of Scotland REC 5
REC reference
25/WS/0162
Date of REC Opinion
9 Oct 2025
REC opinion
Favourable Opinion